STO-CSCO Joint Symposium

Designed for cancer patient care as well as the clinical research community, the STO-CSCO Joint Symposium launched in 2015 with a focus on advances in immuno-oncology and insights into their clinical applications.

For the Chinese Society of Clinical Oncology (CSCO) members looking for a foundational but comprehensive understanding of immunology, the meetings helped to contextualize the educational content by addressing challenges, including the assessment of response and progression and the management of toxicity, and illustrating the role of immunotherapy with real-world data.

This symposium continues to encourage open dialogue and provide opportunities for faculty and attendees to engage.

In 2022 and onward, this Symposium undertakes a comparative analysis of the regulatory requirements for the proper conduction of cancer clinical trials with an aim to harmonize both the high standards needed for cancer clinical trial design, phase I, II, and III, as well as the rigor applied to cancer drug evaluation and approval.